MacroGenics (MGNX) Q4 2025 earnings summary

Executive summary

• Reported 2025 financial results and outlined key upcoming clinical milestones for its antibody-drug conjugate (ADC) pipeline, including initial Phase 1 data for MGC026 and MGC028 in 2026 and an IND submission for MGC030 in Q3 2026.

• Maintains a strong cash position with $189.9 million as of December 31, 2025, and expects cash runway into late 2027.

• Advanced multiple strategic partnerships, remaining eligible for significant milestone and royalty payments.

Financial highlights

• Cash, cash equivalents, and marketable securities were $189.9 million at year-end 2025, down from $201.7 million at year-end 2024.

• Total revenue was $149.5 million for 2025, nearly flat compared to $150.0 million in 2024; contract manufacturing revenue rose to $52.6 million from $13.1 million year-over-year.

• R&D expenses decreased to $147.2 million from $177.2 million, reflecting lower costs for terminated or sold programs.

• SG&A expenses dropped to $39.2 million from $71.0 million, mainly due to lower stock-based compensation and professional fees.

• Net loss was $74.6 million for 2025, compared to $67.0 million in 2024, which included a $36.3 million gain on sale of MARGENZA.

Outlook and guidance

• Expects cash runway into late 2027, supported by current cash, anticipated partner payments, and cost-reduction initiatives.

• Plans initial clinical data disclosures for MGC026 and MGC028 in 2026 and an IND submission for MGC030 in Q3 2026.

• Anticipates a clinical update for the lorigerlimab LINNET study in mid-2026, pending resolution of an FDA partial clinical hold.